116529 ⎘
Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2); Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1) Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
COMPOSITIONS AND METHODS FOR TREATING CANCER WITH SUBCUTANEOUS ADMINISTRATION OF ANTI-PD1 ANTIBODIES
#2COMPOSITIONS AND METHODS FOR TREATING CANCER WITH SUBCUTANEOUS ADMINISTRATION OF ANTI-PD1 ANTIBODIES
#3COMPOSITIONS AND METHODS FOR TREATING CANCER WITH SUBCUTANEOUS ADMINISTRATION OF ANTI-PD1 ANTIBODIES
#4Anti-CD38 Antibodies for Treatment of Light Chain Amyloidosis and Other CD38-Positive Hematological Malignancies
#5PHARMACEUTICAL COMBINATIONS FOR SUBCUTANEOUS ADMINISTRATION AND USE THEREOF
#6CLINICALLY PROVEN SUBCUTANEOUS PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-CD38 ANTIBODIES AND THEIR USES IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE
#7ENGINEERED BACTERIA AND METHODS OF USE IN TUMOR REMODELING
#8Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
#9Hyaluronidase Enzyme Formulations for High Volume Administration
#10ANTIBODIES THAT BIND OX40L AND ANTIBODIES THAT BIND TSLP IN COMBINATION WITH HYALURONIDASE OR A VARIANT THEREOF
#11ANTIBODIES THAT BIND OX40L IN COMBINATION WITH HYALURONIDASE OR A VARIANT THEREOF
#12Antibody Compositions and Methods of Use Thereof
#13HIGH-REACTIVITY HYDROGEL PARTICLE AND PREPARATION METHOD THEREFOR AND USE THEREOF
#14COMBINATION THERAPY WITH ANTIBODY-DRUG CONJUGATES AND HYALURONIDASES
#15COMBINATION THERAPY WITH ANTIBODY-DRUG CONJUGATES AND HYALURONIDASES
#16CONTOUR INJECTION COMPOSITION
#17PHARMACEUTICAL COMPOSITIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND PH20 VARIANTS OR FRAGMENTS THEREOF
#18PHARMACEUTICAL COMPOSITIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND rHuPH20 OR VARIANTS OR FRAGMENTS THEREOF
#19Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof
#20SUBCUTANEOUS FCRN ANTAGONIST FORMULATIONS AND METHODS OF USE THEREOF
#21NOVEL HYALURONIDASE VARIANTS AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
#22HYALURONIDASE HYAL1 VARIANT EXHIBITING ACTIVITY IN NEUTRAL PH
#23PERTUZUMAB PLUS TRASTUZUMAB FIXED DOSE COMBINATION
#24ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF
#25Hyaluronidase Enzyme Formulations for High Volume Administration
#26Tissue Modifier And Uses Therefor
#27LIQUID COMPOSITIONS
#28Antibody Compositions and Methods of Use Thereof
#29RECOMBINANT TMEM2 EXTRACELLULAR DOMAIN AND USES THEREOF
#30PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF
#31PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF
#32PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF
#33PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF
#34PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF
#35CULTURE OF TUMOR INFILTRATING LYMPHOCYTES FROM TUMOR DIGEST
#36POLYPEPTIDES THAT BIND COMPLEMENT COMPONENT C5 OR SERUM ALBUMIN AND FUSION PROTEINS THEREOF
#37Lyophilized Pharmaceutical Compositions Comprising A Lipid Nanoparticle
#38PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF
#39HYALURONIC ACID-PRODUCING RECOMBINANT CELLS
#40MANIPULATION OF ZONA PELLUCIDA TO FACILITATE DELIVERY OF NUCLEIC ACIDS FOR GENE EDITING IN EMBRYO
#41METHOD FOR PRODUCING RECOMBINANT HYALURONIDASE
#42Reducing or Inhibiting Tissue Damage Using Hyaluronidase Administration
#43METHOD FOR PRODUCING RECOMBINANT HYALURONIDASE
#44Hyaluronidase Enzyme Formulations for High Volume Administration
#45Hyaluronidase Enzyme Formulations for High Volume Administration
#46N-terminal and/or C-terminal Cleaved Soluble PH20 Polypeptide and Use Thereof
#47Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof
#48VIRAL PARTICLES WITH MEMBRANE-BOUND HYALURONIDASE
#49Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof
#50Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
#51PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF
#52METHODS FOR TREATING BULLOUS PEMPHIGOID USING FCRN ANTAGONISTS
#53Anti-CD28 Humanized Antibodies Formulated for Administration to Humans
#54SEMAGLUTIDE SOLUBLE MICRONEEDLE COMPOSITION AND PREPARATION METHOD THEREFOR
#55ENGINEERED ONCOLYTIC HERPESVIRUSES
#56Anti-CD38 Antibodies for Treatment of Light Chain Amyloidosis and Other CD38-Positive Hematological Malignancies
#57PHARMACEUTICAL COMPOSITION COMPRISING HUMAN HYALURONIDASE PH20 AND DRUG
#58HYALURONIDASE POLYPEPTIDE FOR USE IN THE TREATMENT OR PROPHYLAXIS OF A NEURODEGENERATIVE DISEASE
#59Lyophilized Pharmaceutical Compositions Comprising a Lipid Nanoparticle
#60CLINICAL FORMULATIONS OF ANTI-TIGIT ANTIBODIES
#61FACILITATED DELIVERY OF CONCENTRATED ANTIBODY FORMULATIONS USING HYALURONIDASE
#62NOVEL RECOMBINANT EXOSOME CONTAINING HYALURONIDASE AND USE THEREOF
#63DIGITAL MICROBIOLOGY
#64PH20 polypeptide variants, formulations and uses thereof
#65SUBCUTANEOUSLY ADMINISTERED ANTIBODY-DRUG CONJUGATES FOR USE IN CANCER TREATMENT
#66SUBCUTANEOUS HER2 ANTIBODY FORMULATIONS
#67Hyaluronidase Enzyme Formulations for High Volume Administration
#68PH20 polypeptide variants, formulations and uses thereof
#69Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof
#70Hyaluronidase enzyme formulations for high volume administration
#71COMPOSITIONS, CELL CONSTRUCTS, AND METHODS OF MAKING AND USING THE SAME
#72Tissue modifier and uses therefor
#73SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODY
#74COMPOSITIONS COMPRISING HYALURONIDASE AND/OR COLLAGENASE AND/OR 4-METHYLUMBELLIFERONE (4-MU) AND METHODS OF TREATMENT USING SAME
#75COMPOSITIONS AND METHODS FOR TREATING CANCER WITH SUBCUTANEOUS ADMINISTRATION OF ANTI-PD1 ANTIBODIES
#76SYSTEMS AND METHODS FOR TREATING CORONAVIRUS
#77METHOD, COMPOSITION, AND ARTICLE OF MANUFACTURE FOR PROVIDING ALPHA-1 ANTITRYPSIN
#78Transdermal Double-layer Microneedle Based on Hydrogen Producing Probiotics and Its Preparation Method and Application
#79PH20 polypeptide variants, formulations and uses thereof
#80PH20 polypeptide variants with a modification at position 309 of the PH20 polypeptide and a method of making thereof
#81METHODS OF TREATING TUMORS
#82PH20 polypeptide variants, formulations and uses thereof
#83PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF
#84PH20 polypeptide variants, formulations and uses thereof
#85Antibody Compositions and Methods of Use Thereof
#86DOSING REGIMEN
#87TREATMENT OR PREVENTION OF A DISEASE OR DISORDER
#88Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
#89CROSS-LINKED HA BEADS, PROCESS FOR MAKING SAME AND USES
#90COMPOSITIONS AND METHODS FOR TREATING SERRATED COLORECTAL CANCER
#91PH20 polypeptide variants, formulations and uses thereof
#92Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone
#93ENHANCEMENT OF CARTILAGE REGENERATIVE ACTIVITY OF STEM CELL POPULATIONS BASED ON REDUCTION OF INTRA-ARTICULAR CELLULAR MATERIAL
#94SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
#95PH20 polypeptide variants, formulations and uses thereof
#96PH20 polypeptide variants, formulations and uses thereof
#97PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF
#98Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib, Mephalan and Prednisone
#99PH20 polypeptide variants, formulations and uses thereof
#100Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof
#101Use of Approved Anti-CD38 Antibody Drug Product in Combination with Pomalidomide and Dexamethasone to Treat Multiple Myeloma
#102MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNE MODULATORS AND ANTI-CANCER THERAPEUTICS IN TUMOR CELLS
#103PH20 polypeptide variants, formulations and uses thereof
#104Subcutaneously administered anti-IL-6 receptor antibody
#105Method for producing recombinant hyaluronidase
#106AEROSOLIZED HYALURONIDASE AND/OR 4-METHYLUMBELLIFERONE COMPOSITIONS AND METHODS OF USING SAME TO TREAT RESPIRATORY DISEASES OR DISORDERS
#107PH20 polypeptide variants, formulations and uses thereof
#108Corticosteriod Reduction in Treatment with Anti-CD38 Antibody
#109MULTI CHAMBER SYRINGE UNIT AND METHOD OF PREPARING A MULTI CHAMBER SYRINGE
#110Subcutaneous HER2 antibody formulations
#111HYALURONIDASE COMPOSITIONS AND METHODS OF USING SAME TO TREAT FIBROSIS
#112SUBCUTANEOUS DELIVERY OF MESSENGER RNA
#113HYALURONIDASE COMPOSITIONS AND METHODS OF USING SAME TO TREAT PERI-ORBITAL HOLLOWNESS AND TEAR THROUGH DEFORMITIES
#114Anti-CD28 Humanized Antibodies Formulated for Administration to Humans
#115HYALURONIDASE COMPOSITIONS AND METHODS OF USING SAME TO TREAT CELLULITE
#116High-efficiency synthesis and high-purity hyaluronic acid, and recombinant for oligosaccharide thereof
#117COMBINATION THERAPY WITH A HYALURONAN-DEGRADING ENZYME AND AN IMMUNE CHECKPOINT INHIBITOR
#118PHARMACEUTICAL COMPOSITION FOR SUBCUTANEOUS INJECTION COMPRISING HUMAN HYALURONIDASE PH20 VARIANT AND DRUG
#119Subcutaneously administered anti-IL-6 receptor antibody
#120Engineered heme-binding compositions and uses thereof
#121ANTICANCER COMBINATIONS
#122Antibody Compositions and Methods of Use Thereof
#123Cleavable lipids
#124Digital microbiology
#125HYALURONIDASE COMPOSITIONS AND METHODS OF USING SAME TO TREAT EDEMA
#126Platform Oncolytic Vector for Systemic Delivery
#127KITS AND METHODS OF USING HYALURONIDASE TO MODIFY POLYSACCHARIDE FILLERS AND DELIVERY SYSTEMS
#128SUBCUTANEOUS THERAPEUTIC ENZYME FORMULATIONS, USES, AND METHODS FOR GENERATING THEREOF
#129Stable Formulations of Programmed Death Receptor 1 (PD-1) Antibodies and Hyaluronidase Variants and Fragments Thereof and Methods of Use Thereof
#130Platform oncolytic vector for systemic delivery
#131Platform oncolytic vector for systemic delivery
#132Pertuzumab plus trastuzumab fixed dose combination
#133Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
#134Hyaluronidase for the prevention, treatment, reduction and/or abolishment of cerebral edema and intracranial pressure
#135PHARMACEUTICAL COMPOSITION FOR SUBCUTANEOUS INJECTION COMPRISING HUMAN HYALURONIDASE PH20 VARIANT AND DRUG
#136Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof
#137Systems and methods for treating coronavirus
#138Reducing or inhibiting ocular damage by hyaluronidase administration
#139PH20 polypeptide variants, formulations and uses thereof
#140PH20 polypeptide variants, formulations and uses thereof
#141SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODY
#142DELIVERING ENZYME USING AN INJECTABLE HYDROGEL DEPOT
#143PLATFORM ONCOLYTIC VECTOR FOR SYSTEMIC DELIVERY
#144NOVEL HYALURONIDASE VARIANTS AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
#145Platform oncolytic vector for systemic delivery
#146SUBCUTANEOUS HER2 ANTIBODY FORMULATIONS
#147Preparation of mammalian oocyte for fertilization via a soluble human PH20 hyaluronidase polypeptide
#148Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies
#149Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof
#150COMPOSITIONS, SYSTEMS, AND METHODS FOR SCAR TISSUE MODIFICATION
#151MULTISPECIFIC MOLECULES COMPRISING A NON-IMMUNOGLOBULIN HETERODIMERIZATION DOMAIN AND USES THEREOF
#152Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib, Mephalan and Prednisone
#153HYALINE CARTILAGE SHAPING
#154PH20 polypeptide variants, formulations and uses thereof
#155Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone
#156Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone
#157PH20 polypeptide variants, formulations and uses thereof
#158Engineered heme-binding compositions and uses thereof
#159Cleavable lipids
#160METHOD, COMPOSITION, AND ARTICLE OF MANUFACTURE FOR PROVIDING ALPHA-1 ANTITRYPSIN
#161COMBINATION OF AN ANTIBODY THAT BINDS TO THE P19 SUBUNIT OF HUMAN IL-23 AND A HYALURONIDASE ENZYME
#162Control of trace metals during production of anti-CD38 antibodies
#163Method of Providing Subcutaneous Administration of Anti-CD38 Antibodies
#164Anti-CD28 Humanized Antibodies Formulated for Administration to Humans
#165HYPOTONIC COMPOSITION FOR FAT DECOMPOSITION AND METHOD FOR PREPARING SAME
#166Kits and methods of using hyaluronidase to modify polysaccharide fillers and delivery systems
#167Medicines for topic use based on sulfated hyaluronic acid as activating or inhibiting agent of the cytokine activity
#168Contact lens use in the treatment of an ophthalmologic condition
#169NOVEL RECOMBINANT EXOSOME CONTAINING HYALURONIDASE AND USE THEREOF
#170METHODS OF SELECTING SUBJECTS FOR COMBINATION CANCER THERAPY WITH A POLYMER-CONJUGATED SOLUBLE PH20
#171USE OF VIRAL VECTORS IN THE TREATMENT OF RETINOBLASTOMA
#172Compositions, cell constructs, and methods of making and using the same
#173Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
#174SYNTHETIC BACTERIA AND METHODS OF USE
#175Subcutaneous formulations of anti-CD38 antibodies and their uses
#176Cleavable lipids
#177Subcutaneous delivery of messenger RNA
#178Use of hyaluronidase for treatment of muscle stiffness
#179Local orbital therapy for thyroid eye disease
#180Subcutaneously administered anti-IL-6 receptor antibody
#181Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
#182Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
#183Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
#184METHOD FOR INCREASING THE BIOAVAILABILITY OF INHALED COMPOUNDS
#185Immune modulation and treatment of solid tumors with antibodies that specifically bind CD38
#186Delivering enzyme using an injectable hydrogel depot
#187COMPOSITIONS, SYSTEMS, AND METHODS FOR SCAR TISSUE MODIFICATION
#188COMBINATION THERAPY WITH AN ANTI-HYALURONAN AGENT AND THERAPEUTIC AGENT
#189Digital microbiology
#190Controlling metabolism by substrate cofeeding
#191Bacterial hyaluronidase and process for its production
#192Engineered heme-binding compositions and uses thereof
#193Subcutaneous HER2 antibody formulations
#194MULTI CHAMBER SYRINGE UNIT AND METHOD OF PREPARING A MULTI CHAMBER SYRINGE
#195Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
#196Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof
#197Anti-CD28 Humanized Antibodies Formulated for Administration to Humans
#198Cleavable lipids
#199DIRECT DETECTION OF MICROORGANISMS IN PATIENT SAMPLES BY IMMUNOASSAY
#200Combination Therapies for CD38-Positive Hematological Malignances with ANTI-CD38 Antibodies and Cyclophosphamide
#201Composition for hypotonic lipolysis and manufacturing method thereof
#202Injection composition comprising hyaluronidase for removal of topical fat
#203Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
#204Cleavable Lipids
#205Mirac proteins
#206Collagenous tissue repair device
#207Subcutaneously administered anti-IL-6 receptor antibody for treatment of juvenile idiopathic arthritis
#208TREATMENT OF INFLAMMATORY CONDITIONS BY MODULATION OF HYALURONAN AND HYALURONIDASE ACTIVITY
#209Combination therapy with an anti-hyaluronan agent and therapeutic agent
#210STABILIZER FOR HYALURONIDASE AND LIQUID FORMULATION COMPRISING HYALURONIDASE
#211Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
#212Hyaline cartilage shaping
#213Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
#214Use of hyaluronidase for treatment of muscle stiffness
#215Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses
#216Medicines for topic use based on sulfated hyaluronic acid as activating or inhibiting agent of the cytokine activity
#217Extracellular hyaluronidase from
#218Method of constructing a recombinant that can produce specific-molecular-weight hyaluronic acids
#219Mirac proteins
#220Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
#221Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies
#222Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
#223Treatment of ophthalmic conditions
#224PH20 polypeptide variants, formulations and uses thereof
#225Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects
#226Anticancer combinations
#227Bacterial hyaluronidase and process for its production
#228Subcutaneous anti-HER2 antibody formulations and uses thereof
#229Contact lens use in the treatment of an ophthalmologic condition
#230Engineered heme-binding compositions and uses thereof
#231Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
#232Treatment of inflammatory conditions with hyaluronan disaccharide
#233Mixture of betamethasone and tranilast with a transdermal gel for scar treatment
#234Stabilizer for hyaluronidase and liquid formulation comprising hyaluronidase
#235DOSING REGIMENS FOR SUBCUTANEOUSLY INFUSIBLE ACIDIC COMPOSITIONS
#236Pharmacological vitreolysis
#237Methods of Treating Serosal Cancer
#238Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor VIII
#239Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
#240THERMALLY STABLE PH20 HYALURONIDASE VARIANTS AND USES THEREOF
#241ANESTHETIC COMPOSITION, FORMULATION AND METHOD OF USE
#242Mirac proteins
#243Convection enhanced delivery apparatus, method, and application
#244Mirac proteins
#245Proteoglycan degrading mutants for treatment of CNS
#246Cleavable lipids
#247Skeletal muscle regeneration promoter
#248Methods for reducing intraocular pressure by administering a soluble hyaluronidase glycoprotein (sHASEGP)
#249Mirac proteins
#250PH20 polypeptide variants, formulations and uses thereof
#251Subcutaneously administered anti-IL-6 receptor antibody
#252Subcutaneously administered anti-IL-6 receptor antibody for treatment of systemic sclerosis
#253Method of reducing insulin resistance by administering a Hyaluronan-degrading enzyme
#254Combination therapy with an anti-hyaluronan agent and therapeutic agent
#255Pharmacological vitreolysis
#256PH20 polypeptide variants, formulations and uses thereof
#257Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
#258Stable formulations of a hyaluronan-degrading enzyme
#259Stable formulations of a hyaluronan-degrading enzyme
#260Subcutaneously administered anti-IL-6 receptor antibody
#261Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
#262Mirac proteins
#263Methods for treating edema by administering a Soluble Hyaluronidase Glycoprotein (sHASEGP)
#264EXTRACELLULAR YALURONIDASE FROM STREPTOMYCES KOGANEIENSIS
#265Large-scale production of soluble hyaluronidase
#266Cosmetic and pharmaceutical compositions having modified proteins in the form of a supramolecular assembly
#267Mirac proteins
#268Disabling autophagy as a treatment for lysosomal storage diseases
#269Hyaluronidase and factor VIII compositions
#270Medicines for topic use based on sulfated hyaluronic acid as activating or inhibiting agent of the cytokine activity
#271Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
#272EXTRACELLULAR YALURONIDASE FROM STREPTOMYCES KOGANEIENSIS
#273Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects
#274Pharmacological vitreolysis
#275PROTEOGLYCAN DEGRADING MUTANTS FOR TREATMENT OF CNS
#276Pharmacological vitreolysis
#277Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
#278Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
#279Large-scale production of soluble hyaluronidase
#280Subcutaneous anti-HER2 antibody formulations and uses thereof
#281Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
#282METHOD, COMPOSITION, AND ARTICLE OF MANUFACTURE FOR PROVIDING ALPHA-1 ANTITRYPSIN
#283Mirac Proteins
#284Methods and materials for reducing biofilms
#285Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
#286Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
#287Convection enhanced delivery apparatus, method, and application
#288FERTILITY ENHANCEMENT USING LIPID CARRIERS AND BIOACTIVE MOLECULES
#289Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
#290Methods for treating a disease characterized by an excess of hyaluronan by administering a soluble hyaluronidase glycoprotein (sHASEGP)
#291AMELIORATING AGENT FOR BRAIN DAMAGE
#292Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
#293Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
#294Anesthetic composition, formulation and method of use
#295Pharmacological vitreolysis
#296Pharmacological vitreolysis
#297Proteoglycan degrading mutants for the treatment of CNS
#298Fusion proteins for the treatment of CNS
#299OLIGORIBONUCLEOTIDES FOR THE TREATMENT OF DEGENERATIVE SKIN CONDITIONS BY RNA INTERFERENCE
#300Pharmacological vitreolysis